A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2013.05.005
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients With Refractory Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2004English

Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Versus Bevacizumab in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Inhibition of Chronic and Acute Skin Inflammation by Treatment With a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

American Journal of Pathology
Forensic MedicinePathology
2008English

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Cancer Research
Cancer ResearchOncology
2008English

Increased Risk of Severe Infections in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis

OncoTargets and Therapy
OncologyPharmacology
2015English

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Biomedical Journal
Medicine
2015English

Serum Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-1 Levels in Patients With Fibromyalgia Syndrome

Archives of Rheumatology
Rheumatology
2019English

The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

2013English

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of C-Met and Vascular Endothelial Growth Factor Receptor 2

Clinical Cancer Research
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy